ArticleJournal of asthma and allergy2021
Association Between a Type 2 Inflammatory Disease Burden Score and Outcomes Among Patients with Asthma.
Article in Journal of asthma and allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Prevalence of type 2 multimorbidities in COPD compared to asthma and relationship to blood eosinophilic counts.ERJ open research · 2026Article
- Coexisting Type 2 Inflammatory Conditions in Patients with Asthma Treated with Dupilumab: the RAPID Registry.Advances in therapy · 2026Observational
- Evaluation of the concordance of asthma remission definitions according to international guidelines in a cohort of patients treated with monoclonal antibodies for severe asthma.Frontiers in pharmacology · 2026Article
- Integrated multi-omics profiling reveals shared mechanistic pathways in asthma-allergic rhinitis comorbidity: A hybrid machine learning framework leveraging Mendelian randomization for precision diagnostics.The World Allergy Organization journal · 2025Article
- Review
- Monosensitization vs Polysensitization in Severe Asthma: Implications for Disease Severity.Journal of asthma and allergy · 2025Article
- Association between type 2 inflammatory diseases and neurodevelopmental disorders in low-birth-weight children and adolescents.Frontiers in psychology · 2024Article
- Severe asthma trajectories in adults: findings from the NORDSTAR cohort.The European respiratory journal · 2023Observational
- Consensus on the management of united airways disease with type 2 inflammation: a multidisciplinary Delphi study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Article
- A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics.The World Allergy Organization journal · 2023Article
- Development of an Asthma Exacerbation Risk Prediction Model for Conversational Use by Adults in England.Pragmatic and observational research · 2023Article
- T-helper cells and their cytokines in pathogenesis and treatment of asthma.Frontiers in immunology · 2023Review
- Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study.Frontiers in immunology · 2023Observational
- Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group.The World Allergy Organization journal · 2022Review
- Characterisation of the Australian Adult Population Living with Asthma: Severe - Exacerbation Frequency, Long-Term OCS Use and Adverse Effects.Pragmatic and observational research · 2022Article
- Quality of Life in Patients With Type 2 Inflammatory Asthma.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough prevalence of co-existing type 2 inflammatory diseases (cT2) in asthma patients has been reported, limited data exist regarding their impact on asthma outcomes.
objectiveTo assess the impact of cT2 burden on asthma outcomes and to evaluate patterns of clustering of cT2 in a real-world setting.
methodsFrom medical records of 4.5 million enrollees in 650 primary care practices in the UK (January 2010-December 2017), patients with ≥1 diagnosis code for asthma at any time pre-index date (date of most recent asthma-related medical encounter) and ≥2 asthma-related prescriptions during the year before index date were categorized into the Global Initiative of Asthma (GINA) guideline severity steps. A cT2 burden score (range 0-9) was assigned based on the total number of co-existing conditions (allergic conjunctivitis, allergic rhinitis, anaphylaxis, eczema/atopic dermatitis, chronic rhinosinusitis, eosinophilic esophagitis, food allergy, nasal polyps, or urticaria) for which patients received a medical diagnosis. Multivariate regression models evaluated associations between cT2 burden score and asthma exacerbations and asthma control. Factor analysis was performed to assess which cT2 comorbidities were correlated and exhibited patterns of clustering.
resultsOverall, 245,893 patients with asthma were included (mean [SD] age 44.8 [22.1] years; 43.8% male). Between 55% (GINA step 1) and 60% (GINA step 5) of asthma patients had a medical diagnosis for ≥1 other type2dx. Patients with increased cT2 burden were significantly more likely to experience asthma exacerbations and less likely to achieve asthma control.
conclusionAsthma patients with a higher cumulative cT2 burden score were more likely to experience worse asthma outcomes than those without any cT2 (burden score of 0).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.